Browsing by Author "Orecchioni S."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside
    (Elsevier Ltd, 2019) Abdel-Aziz A.K.; Saadeldin M.K.; D'Amico P.; Orecchioni S.; Bertolini F.; Curigliano G.; Minucci S.; Department of Experimental Oncology; IEO; European Institute of Oncology IRCCS; Milan; Italy; Department of Pharmacology and Toxicology; Faculty of Pharmacy; Ain Shams University; Cairo; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; 6th October City; Cairo; Egypt; Division of Early Drug Development for Innovative Therapies; IEO; European Institute of Oncology IRCCS; Milan; Italy; Laboratory of Hematology-Oncology; IEO; European Institute of Oncology IRCCS; Milan; Italy; Department of Oncology and Hemato-Oncology; University of Milano; Milan; Italy; Department of Biosciences; University of Milan; Milan; Italy
    The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative breast cancer (BC) expressing PD-L1. Nonetheless, immune checkpoint inhibitors (ICIs) are still challenged by the resistance and immune-related adverse effects evident in a considerable subset of treated patients without conclusive comprehension of the underlying molecular basis, biomarkers and tolerable therapeutic regimens capable of unleashing the anti-tumour immune responses. Stepping back to preclinical models is thus inevitable to address these inquiries. Herein, we comprehensively review diverse preclinical models of BC exploited in investigating ICIs underscoring their pros and cons as well as the learnt and awaited lessons to allow full exploitation of ICIs in BC therapy. 2019 Elsevier Ltd